RE:RE:RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo ClinicONCY has demonstrated that the combination of pelareorep with CAR-T therapy and immune checkpoint inhibitors provides an effective measure to improve both CAR-T and immune checkpoint inhibitor function.
Combining the 3 complementary therapies could prove to be an effective means to increase CAR-T persistence and durability, reverse an immunosuppressive tumor microenvironment (TME), as well as gaining the ability to overcome both antigen escape and resistance induced by T-cell immunotherapy and checkpoint blockade, respectively.